🍀 Spring Date with Fortune, Prizes with Raffle! Growth Value Phase 1️⃣ 7️⃣ Spring Raffle Carnival Begins!
Seize Spring's Good Luck! 👉 https://www.gate.com/activities/pointprize?now_period=17
🌟 How to Participate?
1️⃣ Enter [Square] personal homepage, click the points icon next to your avatar to enter [Community Center]
2️⃣ Complete Square or Hot Chat tasks such as posting, commenting, liking, speaking to earn growth value
🎁 Every 300 points can raffle once, 10g gold bars, Gate Red Bull gift box, VIP experience card and more prizes waiting for you to win!
Details 👉 https://www.gate.com/ann
Biogen (BIIB) 深度解析:從多發性硬化症巨頭轉型為神經創新巨擘,探索其戰略轉變、創新投資與未來願景
Biogen (BIIB) 正在經歷一場重大轉型,從專注於多發性硬化症的公司轉變為神經創新巨頭。儘管過去曾因Aduhelm爭議和專利到期而陷入困境,但該公司最近的2025年第四季度盈利超出預期,以及由Leqembi和Skyclarys等新療法推動的2026年積極指引,顯示在Christopher Viehbacher執行長的領導下前景樂觀。公司面臨競爭和監管障礙,但通過戰略合作、收購以及專注於神經退行性疾病和罕見疾病的研發管線,旨在實現增長。